Merck & Co keeps momentum going with share-boosting financial results - The Pharma Letter

[unable to retrieve full-text content]

Merck & Co keeps momentum going with share-boosting financial results  The Pharma Letter

Merck & Co keeps momentum going with share-boosting financial results - The Pharma Letter

Comments

Post a Comment

Popular posts from this blog

Blue toe syndrome: Causes, treatment, outlook, and prevention - Medical News Today

Image
When one or more of a person's toes starts to look blue or purple, doctors call it blue toe syndrome. There are several triggers, most of which relate to the circulatory system. This article explains what blue toe syndrome is, what it feels like, its causes, and how doctors treat it. It will also explore the possible complications of blue toe syndrome and when to see a doctor. Share on Pinterest Blue toe syndrome can cause muscle pain in the legs, as well as severe pain in the foot. Doctors sometimes call it occlusive vasculopathy or trash foot. Blue toe syndrome is a form of acute digital ischemia. This means it occurs when the toes do not get enough blood. A person's blood carries oxygen from the lungs to every part of their body. Each cell needs oxygen to repair itself and multiply. The blood also brings cells all the nutrients they need and carries away waste products. Not getting enough blood damages cells and the tissues they make up. This can cause the tissue to change c...
Read more

Effect of pharmacogenetic variations on praziquantel plasma ... - Nature.com

Image
Abstract School-based mass drug administration (MDA) of Praziquantel (PZQ) is the global intervention strategy for elimination of schistosomiasis. Genetic variations in drug metabolizing enzymes and transporter proteins influences drug exposure and treatment outcomes, but data on PZQ pharmacokinetics and safety outcomes are scarce. We investigated the effect of pharmacogenetics variations on PZQ plasma concentrations and safety outcomes among 462 Rwandan schoolchildren who received single dose PZQ and albendazole in MDA. Genotyping for common functional variant alleles CYP3A4*1B , CYP3A5 (*3, *6, *7), CYP2C19 (*2, *3, *17), CYP2C9 (*2, *3) and CYP2J2*7 were done. Plasma concentration of PZQ, cis -4-OH-PZQ and trans -4-OH-PZQ were measured using LC/MS/MS. Active safety monitoring was done on days 1, 2, and 7 post-MDA. CYP2C9 and CYP2C19 genotypes were significantly associated with PZQ plasma concentrations and its cis - and trans -4-OH-PZQ/PZQ metabolic ratios (MR). CYP2C9*2 and ...
Read more